These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 18258654)
21. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294 [TBL] [Abstract][Full Text] [Related]
22. CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Janeczko M; Orzeszko A; Kazimierczuk Z; Szyszka R; Baier A Eur J Med Chem; 2012 Jan; 47(1):345-50. PubMed ID: 22115617 [TBL] [Abstract][Full Text] [Related]
23. Characterization of ATM and DNA-PK wild-type and mutant cell lines upon DSB induction in the presence and absence of CK2 inhibitors. Olsen BB; Fritz G; Issinger OG Int J Oncol; 2012 Feb; 40(2):592-8. PubMed ID: 21993375 [TBL] [Abstract][Full Text] [Related]
24. Major tegument protein VP8 of bovine herpesvirus 1 is phosphorylated by viral US3 and cellular CK2 protein kinases. Labiuk SL; Babiuk LA; van Drunen Littel-van den Hurk S J Gen Virol; 2009 Dec; 90(Pt 12):2829-2839. PubMed ID: 19692545 [TBL] [Abstract][Full Text] [Related]
25. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases. Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873 [TBL] [Abstract][Full Text] [Related]
26. Toward the rational design of protein kinase casein kinase-2 inhibitors. Sarno S; Moro S; Meggio F; Zagotto G; Dal Ben D; Ghisellini P; Battistutta R; Zanotti G; Pinna LA Pharmacol Ther; 2002; 93(2-3):159-68. PubMed ID: 12191608 [TBL] [Abstract][Full Text] [Related]
27. Dynamic regulation of a metabolic multi-enzyme complex by protein kinase CK2. An S; Kyoung M; Allen JJ; Shokat KM; Benkovic SJ J Biol Chem; 2010 Apr; 285(15):11093-9. PubMed ID: 20157113 [TBL] [Abstract][Full Text] [Related]
28. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. Schneider CC; Hessenauer A; Montenarh M; Götz C Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628 [TBL] [Abstract][Full Text] [Related]
30. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2. Gyenis L; Kuś A; Bretner M; Litchfield DW J Proteomics; 2013 Apr; 81():70-9. PubMed ID: 23017496 [TBL] [Abstract][Full Text] [Related]
31. TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications. Zień P; Abramczyk O; Domańska K; Bretner M; Szyszka R Biochem Biophys Res Commun; 2003 Dec; 312(3):623-8. PubMed ID: 14680810 [TBL] [Abstract][Full Text] [Related]
32. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies. Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083 [TBL] [Abstract][Full Text] [Related]
34. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Pagano MA; Poletto G; Di Maira G; Cozza G; Ruzzene M; Sarno S; Bain J; Elliott M; Moro S; Zagotto G; Meggio F; Pinna LA Chembiochem; 2007 Jan; 8(1):129-39. PubMed ID: 17133643 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2. Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362 [TBL] [Abstract][Full Text] [Related]
36. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Duncan JS; Litchfield DW Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986 [TBL] [Abstract][Full Text] [Related]
37. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity. Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657 [TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of CK2 inhibitors. Makowska M; Łukowska-Chojnacka E; Wińska P; Kuś A; Bilińska-Chomik A; Bretner M Mol Cell Biochem; 2011 Oct; 356(1-2):91-6. PubMed ID: 21750983 [TBL] [Abstract][Full Text] [Related]
39. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Zień P; Bretner M; Zastapiło K; Szyszka R; Shugar D Biochem Biophys Res Commun; 2003 Jun; 306(1):129-33. PubMed ID: 12788077 [TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase. Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]